Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


P&G recalls Vicks product sans child-resistant packaging

This article was originally published in The Tan Sheet

Executive Summary

Procter & Gamble recalls bonus packs of Vicks DayQuil Cold & Flu 24-Count LiquiCaps that lack child-resistant blister-pack backing. While otherwise safe for patients aged 12 and older, the product is labeled as having child-resistant packaging, the firm said Dec. 18. P&G recently recalled multiple lots of Vicks Sinex 15-mL nasal spray products due to possible bacterial contamination (1"The Tan Sheet" Nov. 23, 2009, In Brief)

You may also be interested in...

Vicks Sinex recalls in U.S., Europe

Procter & Gamble voluntarily recalls three lots of Vicks Sinex 15-mL nasal sprays marketed in Germany, the U.K. and the U.S. after finding the bacteria B. cepacia in products made at its facility in Gross Gerau, Germany. The firm says the recall is precautionary and no illnesses are reported, but the bacteria could cause serious infections for people with a compromised immune system or those with chronic lung conditions. P&G detected the bacteria during routine quality control testing and said analysis shows the problem is limited to a single batch of raw material mixture involving these lots: 9239028831 - Vapospray 12-Hour Decongestant Ultra Fine Mist in the U.S.; 9224028832 - Micromist Aqueous in the U.K.; and 9224028833 - Wick Sinex Schnupfenspray Dosiersystem in Germany

EMA's Decision On Ranitidine Remaining Available Could Come At End Of April

Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.

Perrigo Has Approval For Copy Of OTC Voltaren Arthritis Relief Before GSK Launches The Brand

Perrigo will launch generics of GSK's OTC Voltaren Arthritis Pain drug later in 2020 following FDA approval of its ANDA. GSK, which received FDA's OTC switch approval in February, still hasn't launched the product or indicated when it will.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts